198 related articles for article (PubMed ID: 24149067)
1. Pyrroloquinoline quinone prevents MK-801-induced stereotypical behavior and cognitive deficits in mice.
Zhou X; Chen Q; Hu X; Mao S; Kong Y
Behav Brain Res; 2014 Jan; 258():153-9. PubMed ID: 24149067
[TBL] [Abstract][Full Text] [Related]
2. Supplementation of PQQ from pregnancy prevents MK-801-induced schizophrenia-like behaviors in mice.
Peng Y; Xu D; Ding Y; Zhou X
Psychopharmacology (Berl); 2022 Jul; 239(7):2263-2275. PubMed ID: 35294602
[TBL] [Abstract][Full Text] [Related]
3. The dopaminergic stabiliser ACR16 counteracts the behavioural primitivization induced by the NMDA receptor antagonist MK-801 in mice: implications for cognition.
Nilsson M; Carlsson A; Markinhuhta KR; Sonesson C; Pettersson F; Gullme M; Carlsson ML
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):677-85. PubMed ID: 15276693
[TBL] [Abstract][Full Text] [Related]
4. Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice.
Scorza MC; Castañé A; Bortolozzi A; Artigas F
Neuropharmacology; 2010; 59(1-2):112-20. PubMed ID: 20412811
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity to MK-801 in phospholipase C-β1 knockout mice reveals a specific NMDA receptor deficit.
Gray L; McOmish CE; Scarr E; Dean B; Hannan AJ
Int J Neuropsychopharmacol; 2009 Aug; 12(7):917-28. PubMed ID: 19236734
[TBL] [Abstract][Full Text] [Related]
6. Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-D-aspartate receptor antagonist MK-801 in mice.
Dall'Igna OP; Da Silva AL; Dietrich MO; Hoffmann A; de Oliveira RV; Souza DO; Lara DR
Psychopharmacology (Berl); 2003 Mar; 166(3):258-63. PubMed ID: 12589526
[TBL] [Abstract][Full Text] [Related]
7. Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801.
Pitsikas N; Zisopoulou S; Sakellaridis N
J Neurosci Res; 2006 Aug; 84(2):299-305. PubMed ID: 16710846
[TBL] [Abstract][Full Text] [Related]
8. Modulation of glycine sites enhances social memory in rats using PQQ combined with d-serine.
Zhou X; Liu D; Zhang R; Peng Y; Qin X; Mao S
Behav Brain Res; 2016 Jul; 308():217-21. PubMed ID: 27109337
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical effects of very low dose MK-801.
Tang Y; Zou H; Strong JA; Cui Y; Xie Q; Zhao G; Jin M; Yu L
Eur J Pharmacol; 2006 May; 537(1-3):77-84. PubMed ID: 16626696
[TBL] [Abstract][Full Text] [Related]
10. Kami-ondam-tang, a traditional herbal prescription, attenuates the prepulse inhibition deficits and cognitive impairments induced by MK-801 in mice.
Oh HK; Park SJ; Bae SG; Kim MJ; Jang JH; Ahn YJ; Woo H; Kwon G; Ryu JH
J Ethnopharmacol; 2013 Mar; 146(2):600-7. PubMed ID: 23376282
[TBL] [Abstract][Full Text] [Related]
11. Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action.
Zhou X; Cai G; Mao S; Xu D; Xu X; Zhang R; Yao Z
BMC Psychiatry; 2020 Mar; 20(1):106. PubMed ID: 32143671
[TBL] [Abstract][Full Text] [Related]
12. Effect of pyrroloquinoline quinone on neuropathic pain following chronic constriction injury of the sciatic nerve in rats.
Gong D; Geng C; Jiang L; Aoki Y; Nakano M; Zhong L
Eur J Pharmacol; 2012 Dec; 697(1-3):53-8. PubMed ID: 23063836
[TBL] [Abstract][Full Text] [Related]
13. Enriched environment prevents cognitive and motor deficits associated with postnatal MK-801 treatment.
Nozari M; Shabani M; Hadadi M; Atapour N
Psychopharmacology (Berl); 2014 Nov; 231(22):4361-70. PubMed ID: 24770628
[TBL] [Abstract][Full Text] [Related]
14. Effects of the cognition impairer MK-801 on learning and memory in mice and rats.
van der Staay FJ; Rutten K; Erb C; Blokland A
Behav Brain Res; 2011 Jun; 220(1):215-29. PubMed ID: 21310186
[TBL] [Abstract][Full Text] [Related]
15. NMDA receptor antagonists inhibit apomorphine-induced climbing behavior not only in intact mice but also in reserpine-treated mice.
Kim HS; Rhee GS; Oh S; Park WK
Behav Brain Res; 1999 Apr; 100(1-2):135-42. PubMed ID: 10212060
[TBL] [Abstract][Full Text] [Related]
16. NC-1900, an arginine-vasopressin analogue, ameliorates social behavior deficits and hyperlocomotion in MK-801-treated rats: therapeutic implications for schizophrenia.
Matsuoka T; Sumiyoshi T; Tanaka K; Tsunoda M; Uehara T; Itoh H; Kurachi M
Brain Res; 2005 Aug; 1053(1-2):131-6. PubMed ID: 16051205
[TBL] [Abstract][Full Text] [Related]
17. Anabasine, a selective nicotinic acetylcholine receptor agonist, antagonizes MK-801-elicited mouse popping behavior, an animal model of schizophrenia.
Mastropaolo J; Rosse RB; Deutsch SI
Behav Brain Res; 2004 Aug; 153(2):419-22. PubMed ID: 15265637
[TBL] [Abstract][Full Text] [Related]
18. Expression of NR1, NR2A and NR2B NMDA receptor subunits is not altered in the genetically-inbred Balb/c mouse strain with heightened behavioral sensitivity to MK-801, a noncompetitive NMDA receptor antagonist.
Perera PY; Lichy JH; Mastropaolo J; Rosse RB; Deutsch SI
Eur Neuropsychopharmacol; 2008 Nov; 18(11):814-9. PubMed ID: 18674888
[TBL] [Abstract][Full Text] [Related]
19. Modifications of the behavioral profile of non-competitive NMDA receptor antagonists, memantine, amantadine and (+)MK-801 after chronic administration.
Hesselink MB; Smolders H; De Boer AG; Breimer DD; Danysz W
Behav Pharmacol; 1999 Feb; 10(1):85-98. PubMed ID: 10780305
[TBL] [Abstract][Full Text] [Related]
20. MK-801 suppresses muricidal behavior but not locomotion in olfactory bulbectomized rats: involvement of NMDA receptors.
Ho YJ; Chen KH; Tai MY; Tsai YF
Pharmacol Biochem Behav; 2004 Mar; 77(3):641-6. PubMed ID: 15006477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
